The mechanism underlying the SLC13A5, AT-1, and ATase duplication-associated syndromes differs substantially from the above and offers a unique model where specific metabolic outputs disrupt the proteostatic functions of the ER altering the quality of the secretome (discussed later). The gene discussed is SLC33A1; the disease is Down syndrome.